Inventiva discontinues lanifibranor for systemic sclerosis

Inventiva S.A. (Euronext:IVA) discontinued development of lanifibranor (IVA337) to treat diffuse cutaneous systemic sclerosis after the

Read the full 160 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE